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Abstract

The Journal of Experimental Medicine

An important pathway for immune tolerance is provided by thymic-derived CD25 CD4 T
cells that suppress other CD25 autoimmune disease–inducing T cells. The antigen-presenting
cell (APC) requirements for the control of CD25 CD4 suppressor T cells remain to be identified, hampering their study in experimental and clinical situations. CD25 CD4 T cells are
classically anergic, unable to proliferate in response to mitogenic antibodies to the T cell receptor complex. We now find that CD25 CD4 T cells can proliferate in the absence of added
cytokines in culture and in vivo when stimulated by antigen-loaded dendritic cells (DCs), especially mature DCs. With high doses of DCs in culture, CD25 CD4 and CD25 CD4
populations initially proliferate to a comparable extent. With current methods, one third of
the antigen-reactive T cell receptor transgenic T cells enter into cycle for an average of three
divisions in 3 d. The expansion of CD25 CD4 T cells stops by day 5, in the absence or presence of exogenous interleukin (IL)-2, whereas CD25 CD4 T cells continue to grow. CD25
CD4 T cell growth requires DC–T cell contact and is partially dependent upon the production
of small amounts of IL-2 by the T cells and B7 costimulation by the DCs. After antigen-specific
expansion, the CD25 CD4 T cells retain their known surface features and actively suppress
CD25 CD4 T cell proliferation to splenic APCs. DCs also can expand CD25 CD4 T cells
in the absence of specific antigen but in the presence of exogenous IL-2. In vivo, both steady
state and mature antigen-processing DCs induce proliferation of adoptively transferred CD25
CD4 T cells. The capacity to expand CD25 CD4 T cells provides DCs with an additional
mechanism to regulate autoimmunity and other immune responses.
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Introduction
Evidence is accumulating that immunologic self-tolerance
in the periphery can be maintained by CD25 CD4 regulatory T cells, which constitute 5–10% of CD4 peripheral
T cells (1–6). CD25 CD4 suppressors also play important
roles during other immune responses, as in infection (7–9),
tumors (10, 11), transplants (12), and graft versus host disease (13). A classical feature of CD25 CD4 regulatory T
cells is that they are anergic upon TCR-mediated stimulation in vitro, failing to undergo proliferation, yet they
suppress the activation and proliferation of other CD4 and

CD8 T cells (14–16). CD25 CD4 T cells can inhibit
IL-2 transcription by responder T cells and because of their
anergy, it is unclear how the numbers of regulatory T cells
are sustained and expanded (14–16). Nonetheless, CD25
CD4 T cells are able to undergo homeostatic expansion
when transferred into lymphocyte-deficient hosts (17, 18).
Molecular mechanisms for the function of suppressive
CD25 CD4 T cells are being identified. Cytotoxic T
lymphocyte–associated antigen 4 (CTLA-4)* is expressed
and required for the activation of suppression (19, 20),
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Materials and Methods
Mice. BALB/c and C57BL/6 mice were purchased from
Taconic Farms. OVA-specific, MHC class II–restricted, TCR
transgenic mice were DO11.10 (H-2d; provided by Dr. P. Marrack, National Jewish Medical and Research Center, Denver,
CO) and OT-II (H-2b; provided by F. Carbone, University of
Melbourne, Parkville, Victoria/Australia). C57BL/6, CD80/
CD86/, and IL-2/ mice were from The Jackson Laboratory,
and BALB/c IL-2/ mice were provided by Drs. M. and J. Lafaille (New York University, New York, NY). Specific pathogen-free mice of both sexes were used at 6–12 wk of age according to institutional guidelines.
Antibodies and Reagents. mAbs for MHC class II (M5/114,
TIB120), B220 (RA3-6B2, TIB146), CD8 (3-155, TIB211),
CD4 (GK1.5, TIB207), CD3 (145-2C11, CRL1975), and HSA
(J11d, TIB183) were from American Type Culture Collection.
FITC-conjugated anti-CD25 (7D4), I-Ad (AMS-32), Gr1 (RB68C5), CD11c (HL3), and CD4 (H129.19), PE–anti-CD8a (536.7), B220 (RA3-6B2), CD86 (GL1), and CTLA-4 (UC104F10-11), biotinylated anti-CD25 (7D4), I-Ab (AF6-120.1), I-Ad
(AMS-32), and mouse anti–human V8 (BV8), APC–antiCD11c (HL3), CD62L (MEL-14), CD25 (PC61), and CD4
(RM4-5), and PE-streptavidin, CyChrome-streptavidin, and
PerCP streptavidin were from BD Biosciences. FITC- and biotin-KJ1.26 antibody to the TCR of DO11.10 T cells was from
Caltag. Purified antibody to CD3 (145-2C11), CD25 (PC61),
CD49b/Pan NK cells (DX5), CD16/CD32 (2.4G2), and control
rat IgG were from BD Biosciences. We purchased biotin goat
anti–GITR and IFN- from R&D Systems, rHu IL-2 from Chiron Corp., anti-CD11c, CD43, CD19, CD5, FITC, and PE microbeads from Miltenyi Biotec, carboxyfluorescein diacetate suc-
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cinimidyl ester (CFSE) from Molecular Probes, and intracellular
staining kit for CTLA-4 and OptEIATM kits for mouse IL-2, IL-4,
IL-10, and IFN- ELISA from BD Biosciences.
Proliferation Assays. Spleen and lymph node cell suspensions
were depleted of J11d, CD8, and DX5 cells by panning. The
remaining CD4-enriched cells were stained with antibodies to
CD4 and CD25 (7D4) and sorted on a FACS Vantage™ (BD
Biosciences) into CD25 and CD25 populations (97% and
99% pure). 104 T cells were cultured for 3 d with APCs, either
103–104 DCs or 5–10  104 fresh spleen cells (irradiated with 15–
20 Gy) in 96-well round-bottomed plates (Corning). 1 mg/ml
OVA protein was pulsed into the BM cultures for 16 h before
harvesting the DCs, or 1 g/ml DO11.10 OVA 323–336 peptide
was added continuously to the APC–T cell cocultures. To assess
suppression by CD25 CD4 T cells, 5–10  104 whole spleen
cells were used to stimulate mixtures of 1–2  104 CD25 and
1–2  104 CD25 CD4 T cells from DO11.10 or BALB/c mice
(14–16, 21). 5% vol/vol supernatant of 2C11 hybridoma cells secreting anti-CD3 antibody or 1 g/ml purified antibody was
added for stimulation. [3H]thymidine uptake (1 Ci/well; NEN
Life Science Products) by proliferating lymphocytes was measured at 60–72 h. To assess the need for cell to cell contact,
CFSE-labeled T cells were placed on both sides of a transwell
chamber (Costar). The outer well contained DCs and T cells
(3  105 each) and anti-CD3 antibody to stimulate cell growth,
and the inner well had 5  104 T cells without or with either
anti-CD3 or 5  104 DCs to determine if soluble factors from the
outer well could drive T cell expansion.
BM-derived DCs (BM-DCs). These were prepared with GMCSF (28). In brief, BM cells were grown in RPMI 1640 containing 5% FCS and the supernatant (3% vol/vol) from J558L cells
was transduced with murine GM-CSF (provided by A. Lanzavecchia, Basel Institute, Basel, Switzerland). On day 5, OVA (Seikagaku), which contained 20 pg endotoxin/mg protein, was
added in some wells at 1 mg/ml with or without LPS (SigmaAldrich) at 50 ng/ml for 16 h. On day 6, cells were collected and
washed with HBSS. After Fc block, the cells were stained with
FITC–anti-Gr1 mAb and PE–anti-CD86. After washing, the
cells were incubated with anti-FITC microbeads and put onto
MACS columns (Miltenyi Biotec) to eliminate residual Gr1
granulocytes. The negative cells were then incubated with anti–
PE-MACS beads and put onto MACS columns to provide
CD86high mature and CD86low immature DCs, which were irradiated with 15–20 Gy. In some experiments the CD86high and
CD86low DCs were sorted by flow cytometry with similar results.
For fixation, DCs were incubated with 0.75% paraformaldehyde
for 30 min on ice. To measure IL-2 production, fixed or nonfixed DCs were cultured for 1 d with 0, 10, 100, or 1,000 ng/ml
LPS and the concentration of IL-2 was measured by ELISA.
Other APCs. Spleen CD8 and CD8 DCs were prepared as
previously described (29). Splenic B cells were prepared with
CD19 MACS beads from spleen high density populations. Peritoneal exudate cells (PECs) were collected by washing the peritoneal cavity with PBS. 4 d earlier, some mice were given thioglycollate (TGC; Difco). In some instances, 2 d after injection of
TGC, mice were given 100 U IFN- i.p. to up-regulate MHC
class II on the macrophages. Lymph node CD11c DCs were isolated with CD11c beads (29). For priming with CFA (Difco), a 1:1
emulsion of CFA and PBS was injected s.c. (50 l/paw) and 5 d
later, lymph node CD11c DCs were prepared.
Proliferation of CFSE-labeled CD25 and CD25 CD4 T
Cells. For in vitro studies, FACS®-purified CD25 or CD25
CD4 T cells were incubated with 1 M CFSE for 10 min at
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whereas glucocorticoid-induced TNF receptor (GITR)
signaling of CD25 CD4 T cells renders them nonsuppressive (21, 22). The transcription factor, Foxp3, programs
the development of regulatory T cells (23–25). When DCs
are stimulated through Toll-like receptors, they can produce IL-6 and unknown soluble factor(s), rendering the
CD25 CD4 T cells resistant to suppression by CD25
CD4 T cells (26). However, the APCs that control the
expansion of the “anergic” but suppressive CD25 CD4
T cells remain to be identified, hampering their experimental study and use in many of the important clinical
conditions summarized above.
We have now investigated the interaction between different types of APCs and CD25 CD4 regulatory T cells.
We find that CD25 CD4 T cells are not anergic, as long
as the cells are stimulated with DCs. In fact, the CD25
CD4 T cells can proliferate in an antigen-specific manner
in vitro and in vivo for several days at a rate that is comparable to that seen in CD25 CD4 T cells. CD25 CD4 T
cells expanded by mature DCs, retain high expression of
CTLA-4 and GITR, and are enriched in suppressor function. Importantly, CD25 CD4 T cells proliferate extensively in response to DCs, processing protein antigens in
the steady state or after maturation in vivo in lymph nodes,
thereby providing DCs with another mechanism for their
emerging roles in the maintenance of peripheral immune
tolerance (27).

37 C and 104 T cells were cultured with OVA-pulsed or -unpulsed
CD86 BM-DCs for 3 d before FACS® analysis for proliferation
(progressive halving of the CFSE label). Dead cells were gated
out with TOPRO-3 iodide (Molecular Probes) labeling. For in
vivo proliferation, CD25 or CD25 CD4 T cells purified by
flow cytometry or by MACS were labeled with 5 M CFSE, and
0.7–1.0  106 T cells were injected i.v. into BALB/c recipients.
1 d later, 2  105 OVA-pulsed or -unpulsed, LPS-matured marrow DCs (depleted of macrophages by adherence to plastic for
2 h) were injected s.c. in each paw. Alternatively, the mice were
given 25 g soluble endotoxin-free OVA into the paw. It is
known that DCs in the steady state are the major cell type presenting OVA to T cells in the steady state (30).

BM-DCs Stimulate CD25 CD4 T Cell Proliferation–
Uptake Studies. To follow the antigendependent growth of CD25 and CD25 CD4 T cells,
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[3H]thymidine

Figure 1. DCs stimulate CD25 CD4 T cell growth. (A) 104 CD25 or CD25 CD4 FACS®-purified (top) DO11.10 OVA-specific T cells were
cultured for 3d with 105 spleen APCs or 5  103 CD86 mature DCs and anti-CD3 mAb. [3H]thymidine uptake was assessed (60–72 h). (B) As in A, but
T cells were from two OVA-specific TCR transgenic mice, DO11.10 and OT-2, and the DCs were pulsed or not pulsed with 1 mg/ml OVA protein.
(C) CD25 CD4 T cells from wild-type BALB/c mice () proliferate in response to DCs presenting anti-CD3 (right) but not OVA (left). (D and E)
Day 6 marrow DCs were FACS® separated into mature CD86high and immature CD86low CD11c subsets (D) and cultured with CD25 CD4 DO11.10
T cells (E) with OVA protein (1 mg/ml pulsed onto the DCs) or 1 g/ml OVA 323–339 peptide continuously. One representative result of at least three
experiments is shown.
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Results

we purified these populations from OVA-specific TCR
transgenic DO11.10 mice by FACS® (Fig. 1 A, top). This
step was the limiting one for the experiments, because only
2–3  106 purified CD25 CD4 T cells were obtained
from eight mice. When standard bulk populations of spleen cells
were tested as APCs, we found as expected from much earlier work (beginning with references 14 and 15) that the
CD25 CD4 T cells were anergic or nonresponsive to
stimulation with anti-CD3 mitogenic antibody, whereas
the CD25 CD4 T cells responded (Fig. 1 A, bottom).
Furthermore, mixtures of CD25 and CD25 CD4 T
cells were suppressed, failing to proliferate to anti-CD3
when spleen cells were the APCs (Fig. 1 A). In contrast,
when we tested DCs (even in low numbers) generated
from BM progenitors with GM-CSF, the CD25 CD4 T
cells were now responsive to anti-CD3, and suppression
was no longer evident in mixtures of CD25 and CD25
CD4 T cells (Fig. 1 A). Strong responses were repeatedly
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studies indicated that as little as 0.01 g/ml peptide could
stimulate the proliferation of CD25 CD4 T cells significantly (unpublished data). Also, the DCs were equally active if they had been matured spontaneously (Fig. 1 D) or
in the presence of LPS (not depicted), the latter to increase
the yield of mature DCs. Therefore, CD25 CD4 T cells
are not intrinsically unresponsive to TCR stimulation but
are able to proliferate to anti-CD3 and to antigen when
presented by DCs and in the absence of exogenous growth
factors like IL-2.
BM-DCs Stimulate CD25 CD4 T Cell Proliferation–
Extent of Cell Division. To certify the capacity of CD25
CD4 T cells to proliferate to antigen-presenting DCs, we
documented their growth in two other ways. First, the
number of CD25 CD4 cells expanded about fivefold in
3–5 d in the presence of OVA antigen (Fig. 2 A, right) at
the same time that DNA synthesis was robust, 50–100 

Figure 2. A large fraction of
CD25 CD4 T cells are driven
into multiple cell cycles by DCs.
(A) As in Fig. 1, but the kinetics
of proliferation ([3H]thymidine
and cell counts) were both followed. (B) 104 CFSE-labeled T
cells were cultured for 3 d with
104 CD86 mature BM-DCs either OVA-pulsed (DC-OVA) or
unpulsed (DC), before FACS®
analysis. (C) Quantitative estimation of the number of T cells entering the cell cycle, and the
number of mitotic events, was
performed as follows. 104 CFSElabeled CD25 CD4 T cells
were cultured for 72 h with 1
mg/ml OVA-pulsed CD86
BMDCs (104), and analyzed for
dilution of CFSE label (C). The
percentage of total CD4 events
under each division peak (a) was
experimentally determined (b).
In this experiment, 24,000 live
T cells were recovered, from
which the absolute T cell count
in each division peak at the time
of harvest could be calculated
(c). The absolute number of
original, or precursor, T cells required to have generated these
daughters is extrapolated by dividing the numbers of cells in
column c by the number of divisions, 2 n (d). The sum of the
number of precursors giving rise
to each peak represents the
number of T cells at day 0 that
entered cell cycle, which in this
experiment was 3,020 (the sum
of column d) from a starting
number of 10,000 T cells, giving
a precursor frequency of 30%.
The number of progeny in each peak (c) minus the number of precursors giving rise to the progeny (d) gives the number of mitotic events (e). The sum
of these events represents the total number of cell divisions that occurred in the T cell subset by the time of harvest. (D) The experiment and calculation
in C was performed in a total of six experiments where the TCR stimulus was specific OVA antigen (n 3) or anti-CD3 antibody (n 3).
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observed with CD25 CD4 T cells from two different
OVA-specific transgenics, DO11.10 and OT-II, and over a
broad range of DC doses in the presence of OVA antigen
(Fig. 1 B). Non-TCR transgenic BALB/c T cells also responded to DCs presenting anti-CD3 but did not respond
to DCs presenting OVA, whereas DO11.10 T cells responded to both (Fig. 1 C), confirming that the responses
by OVA-reactive CD25 CD4 transgenic T cells were
antigen-specific.
To evaluate the effect of DC maturation on their capacity to stimulate CD25 CD4 T cells, we sorted the BMDCs into mature and immature populations, expressing
high and low levels of the CD86 T cell costimulatory molecule, respectively (Fig. 1 D). Both were active, but the
mature CD86high DCs were better stimulators for T cell
proliferation when either OVA protein or preprocessed
peptide was the source of antigen (Fig. 1 E). Dose response
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at least one mitotic event during 3 d of culture (Fig. 2 D).
During the same time period, a similar frequency of the
CD25 CD4 T cells entered cell cycle, but the number of
mitotic events was actually less (Fig. 2 D). We also verified
that the major CD62L and minor CD62L subsets of
CD25 CD4 T cells responded comparably to DC-OVA
(not depicted). Therefore, in the first 3 d of culture, both
CD25 CD4 and CD25 CD4 are stimulated by DCs to
enter cell cycle and expand significantly.
Partial IL-2 Dependence of DC-induced CD25 CD4 T
Cell Proliferation, Including IL-2–induced, Antigen-independent
Proliferation. Because the CD25 marker for regulatory T
cells is a component of the IL-2 receptor, we tested the role
of IL-2 in our cultures. The addition of exogenous IL-2
only induced a minute response in the CD25 CD4 T
cells themselves (Fig. 3 A, top; note the units on the y axis).

Figure 3. Role of IL-2 in CD25 CD4 T cell proliferation. (A) [3H]thymidine uptake by CD25 or CD25 CD4 T cells alone (top), or T cells
stimulated by CD86 DCs not pulsed (middle) or pulsed (bottom) with OVA protein IL-2 or PC61 anti–IL-2R mAb. (B) As in A, but IL-2 effects on
[3H]thymidine uptake and cell counts were assessed with time. (C) As in A, but anti–IL-2R mAb or control rat IgG was added to CD25 CD4 T cells
stimulated with DCs from wild-type (WT) or IL-2/ mice plus OVA peptide at 1 g/ml for 3 d. The numbers above the bars indicate the amount of
IL-2 detected by ELISA in the same culture. (D) IL-2 production (ELISA) after stimulation with DC-OVA or DCs. Statistical significance was determined using the unpaired Student’s t test. *, P 0.01.
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103 cpm in cultures of 104 T cells (Fig. 2 A, left). However,
the CD25 CD4 T cells did not expand beyond the initial
3–5 d of culture, whereas CD25 CD4 cells expanded in a
sustained fashion (Fig. 2 A), the latter most likely because
of the production of large amounts of IL-2 as will be
shown below. We also added antigen-bearing DCs to
CD25 CD4 T cells that had been expanded previously
for 1 wk in culture, and again we observed a two- to threefold expansion in T cell numbers (not depicted).
We then compared the proliferation of CFSE-labeled
CD25 CD4 and CD25 CD4 T cells. Both populations
underwent several cycles of cell division in 3 d (Fig. 2 B).
Using this data and the approach of Wells et al. (31), in six
experiments (three each using DCs to present anti-CD3
antibody or specific OVA antigen), we found that about
one third of the cultured CD25 CD4 T cells underwent

The Journal of Experimental Medicine

dehyde-fixed DCs. We confirmed the findings of Granucci
et al. (32) that DCs in the absence of T cells produced IL-2
upon stimulation and that this could be abolished by fixation of the DCs in paraformaldehyde (not depicted). DCs
from IL-2/ mice (Fig. 3 C) were active in stimulating
CD25 CD4 T cells, and the growth was partially blocked
with anti-CD25 antibody (Fig. 3 C). We then measured
IL-2 production in the IL-2/ DC–T cell cocultures because it is known that CD25 CD4 T cells do not produce detectable IL-2 in response to splenic APCs and
anti-CD3 (14, 15). However, we found that the culture
supernatants from CD25 CD4 T cells and OVA-DCs
from wild-type mice did contain some IL-2 by ELISA
(concentrations of IL-2 is shown above the bars in Fig. 3
C), but primarily in the first 3 d of the cultures and only at
a small fraction of the levels induced by DCs from CD25
CD4 T cells (Fig. 3 D). IL-10 was undetectable by ELISA
in the culture supernatants of CD25 T cells stimulated by
DC-OVA ( 40 pg/ml), and other cytokines like IFN-
( 40 pg/ml) and IL-4 ( 10 pg/ml) were also absent
(ELISA data is not depicted).
To assess the potential role of cell surface costimulators
on DCs, we tested if formaldehyde-fixed DCs could induce T cell proliferation. Live DCs were more effective
than fixed DCs (Fig. 4 A, threefold higher doses of DCs
were used; Fig. 4 B) and anti–IL-2R antibody could par-

Figure 4. Membrane costimulation of CD25 CD4 T cells by DCs. (A) Comparison of T cell responses to live (top, T/DC ratio of 1:1) or formaldehyde-fixed (bottom, T/DC ratio of 1:3) CD86 mature marrow DCs plus DO11.10 peptide at 1 g/ml for 3 d in the presence of the indicated concentrations of control and anti–IL-2R mAb. Statistical significance was determined using the unpaired Student’s t test. *, P 0.01. (B) Same as A, but the
activity of aldehyde-fixed DCs were studied with DCs that were charged with OVA (DC-OVA) or not (DC), and then added to CD25 CD4 and
CD25 CD4 T cells in the presence or absence of IL-2, with only the former subset responding to IL-2 in the absence of OVA (top left). (C) 104
marrow DCs were generated from wild-type (WT) or CD80/CD86 knockout mice and matured in 50 ng/ml LPS before culture with 104 CD25 or
CD25 CD4 T cells (purified from OT-II mice spleen and lymph node cells) for 3 d with or without 0.5 g/ml OVA peptide. The degree of proliferation was assessed by incorporation of [3H]thymidine for the last 12 h. One representative result of three independent experiments is shown.
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However, IL-2 induced more significant proliferation of
CD25 CD4, but not CD25 CD4, T cells in the presence of DCs without OVA antigen, and this could be
blocked by anti–IL-2R antibody completely (Fig. 3 A,
middle). DCs with OVA stimulated CD25 CD4 T cell
growth 5–10-fold more vigorously than in the absence of
antigen (compare the y axes of Fig. 3 A, middle and bottom). The response of CD25 CD4 T cells was enhanced
by low doses of exogenous IL-2 (Fig. 3 A). Proliferation in
the absence of IL-2 was partially blocked (52.0 9.3%,
n 5) by anti-CD25 antibody, whereas IL-2 and anti–IL2R antibody had little or no effect on the responses of
CD25 CD4 T cells (Fig. 3 A, bottom). When the kinetics of the response to exogenous IL-2 was monitored, the
stimulation of CD25 CD4 T cell growth was evident
primarily in the first 3–5 d in culture (Fig. 3 B, left). In
contrast, CD25 CD4 T cells responded continuously for
1 wk to DCs, without any boost by exogenous IL-2 (Fig. 3
B, right). Thus, IL-2 enhances antigen-dependent and -independent proliferation of CD25 CD4 T cells in response
to DCs.
CD25 CD4 T Cells Produce Low Levels of IL-2 in Response to DCs, and Their Proliferation Is Partially Dependent on
B7 Costimulation. We first tested if the observed proliferative responses to DCs could be attributed to IL-2 made by
the DCs themselves, using DCs from IL-2/ mice and al-
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These T cells, when cultured in the inner well with antiCD3 or DC only, could undergo at most a single cell division whether or not the outer well was empty or contained mixtures of CD25 CD4 T cells with both DC
and anti-CD3 antibody (Fig. 5, top). However, most
CD25 CD4 T cells cultured together with DCs and
anti-CD3 divided two to five times (Fig. 5), indicating
that cell–cell contact with DCs was important for initiating their growth.
Retention of Suppressive Activity in CD25 CD4 T Cells
Expanded by DCs. It was important to verify that the
CD25 CD4 T cells retained their known phenotypic
markers and suppressive properties after DC-induced expansion, which was 3–10-fold in the absence and presence
of exogenous IL-2, respectively. In terms of phenotype, the
expanded CD25 CD4 T cells maintained higher expression of CTLA-4 and GITR (19–22) relative to CD25
CD4 responders (Fig. 6 A). During expansion, expression
of CD62L (the lymph node homing receptor) decreased on
many of the CD25 CD4 T cells, but after 7 d of culture,
most cells expressed CD62L (not depicted), as is the case
for most regulatory T cells in lymphoid organs (33).
CD25 CD4 T cells proliferating in response to DCOVA up-regulated expression of CD25, CTLA-4, and
GITR, and almost all cells had little or no CD62L at day 7
(Fig. 6 A and unpublished data). The percentage of CD25
CD4 T cells expressing the KJ1.26 clonotypic TCR

Figure 5. CD25 CD4 T cells must contact DCs to proliferate actively. CFSE-labeled CD25 CD4 T cells (top) or CD25 CD4 T cells (bottom)
and the indicated stimuli were added to the inner and outer wells of transwell chambers, and the dilution of CFSE label per cell was followed by FACS®
after 3 d of culture. Dead cells were gated out by TOPRO-3 staining. One representative result of three independent experiments is shown.
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tially block T cell proliferation (Fig. 4 B). Nevertheless, aldehyde-fixed DCs stimulated the growth of CD25 CD4
and CD25 CD4 T cells in the presence of OVA antigen.
In the absence of OVA but with IL-2, live and fixed DCs
also stimulated the growth of some CD25 CD4, but not
CD25 CD4, T cells (Fig. 4 B).
The activity of aldehyde-fixed DCs suggested that a
membrane-bound costimulatory molecule was contributing to the T cell response. In fact, DCs prepared from
mice genetically deleted of the CD80 and CD86 costimulatory molecules (also known as B7-1 and B7-2) were
only one third as efficient at stimulating the proliferation
of CD25 CD4 cells (Fig. 4 C). The proliferation of the
transgenic CD25 CD4 T cells in parallel was actually
maintained with B7-deficient DCs in this system in
which the DC/T cell ratio was 1:1 (Fig. 4 C), but B7deficient DCs were less active with lower DC/T cell
ratios of 1:25 (not depicted). In sum, the response of
CD25 CD4 T cells to antigen-bearing DCs is substantially blocked by anti-CD25 antibody. The requisite IL-2
is produced in small amounts by the responding T cells,
and B7 costimulation contributes significantly to CD25
CD4 T cell proliferation.
The Proliferation of CD25 CD4 T Cells Induced by
DCs Requires DC–T Cell Contact. Transwell experiments
were then performed to show the need for DC–T cell
contact in the proliferation of CD25 CD4 T cells.
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marker was enriched after expansion, 80 versus 60% initially, and the mean fluorescence for KJ1.26 expression increased slightly (Fig. 6 B), indicating that DC-OVA were
selectively expanding OVA-specific cells.
When the functions of the expanded CD25 CD4 cells
were tested with whole spleen APCs, the T cells were indeed anergic upon challenge with OVA or anti-CD3 (Fig.
6 C, groups 2 and 5, respectively) in contrast to the robust
responses of CD25 CD4 cells (Fig. 6 C, groups 1 and 4).
Furthermore, the expanded CD25 CD4 cells could actively suppress the responses of CD25 CD4 cells to OVA
or anti-CD3 (Fig. 6 C, groups 3, 6, and 8). The CD25
CD4 T cells expanded by DC-OVA were more active on
a per cell basis than freshly isolated CD25 CD4 T cells
when tested for their capacity to suppress OVA-specific T
cell responses (Fig. 6 D). These findings on the retained
phenotype and function of CD25 CD4 T cells also were
noted after expansion with DC-OVA plus IL-2 (Fig. 6 D,
bottom). In summary, after expansion by DCs, CD25
CD4 T cells express their characteristic markers and regulatory function.
242

Weak Stimulation of CD25 CD4 Suppressor T Cells
by Other Types of APCs. To compare the responses of
CD25 CD4 T cells to various sources of APCs, we first
examined DCs from different sites. Splenic CD8 and
CD8 DC subsets were tested immediately upon isolation
or after maturation overnight with LPS. These stimulated
CD25 CD4 T cells but to a much lesser degree than
BM-DCs with either OVA protein or peptide as antigen
(Fig. 7, A and B). These cultured splenic DCs had similar
surface levels of CD80 and CD86 compared to the BMDCs (not depicted). However, both splenic- and marrow-derived DCs were comparably potent in stimulating
CD25 CD4 T cells (Fig. 7 A). CD19 B cells stimulated
with LPS overnight could elicit some T cell proliferative
responses from CD25 CD4 but not from CD25 CD4
T cells (Fig. 7 A). Normal and TGC-elicited peritoneal
macrophages were weak stimulators of both CD25 and
CD25 CD4 T cells, even when the macrophages were
taken from mice given IFN- i.p. to enhance expression of
antigen-presenting MHC class II products (Fig. 7 C). Because BM-DCs were generated in the presence of the in-
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Figure 6. CD25 CD4 T cells expanded by mature BM-DCs retain phenotype and function. (A) Surface markers of CD25 CD4 and CD25
CD4 T cells after 7-d expansion by mature CD86 DC-OVA (shaded histogram, isotype control). (B) As in A, but the expression of the KJ1.26 clonotypic receptor in CD25 CD4 T cells is shown before and after 7 d of culture with DC-OVA. (C) 104 DO11.10 T cells were cultured for 7 d with an
equal number of OVA-pulsed CD86 marrow DCs. CD11c DCs were eliminated by MACS, and then the recovered T cells were used to respond to
5  104 splenic APCs, or to suppress fresh CD25 CD4 T cells in the presence of 1 g/ml OVA peptide (top) or anti-CD3 mAb (bottom). (D) CD25
CD4 T cells purified from DO11.10 mice were expanded with OVA-pulsed mature DCs for 7 d as in C, with or without exogenous 100 U/ml IL-2.
Fresh or cultured CD25 CD4 T cells were then mixed with freshly isolated CD25 CD4 T cells from DO11.10 mice at the indicated ratios and cultured for 3 d. The degree of proliferation was assessed by incorporation of [3H]thymidine for the last 12 h. Representative results of three or more similar
experiments. Statistical significance was determined using the unpaired Student’s t test. *, P 0.01.
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TCR transgenic mice, labeled them with CFSE, injected
the T cells into naive BALB/c mice, and followed their
proliferation and distribution in response to challenge with
OVA antigen. In each of three experiments, CD25 CD4
T cells proliferated in the draining but not distal lymph
nodes (Fig. 8 A) and spleen (not depicted) of mice challenged with DC-OVA. As expected, DC-OVA also induced extensive proliferation of CD25 CD4 T cells in
lymph nodes draining the DC injection site (Fig. 8 A). The
proliferation was OVA antigen-dependent, being absent in
CD25 or CD25 CD4 T cells when animals received
DCs that had not been exposed to OVA (Fig. 8 A). The
total number of clonotype (KJ1.26)-positive T cells recovered upon stimulation with DC-OVA versus DC was increased 8–10-fold when either CD25 or CD25 CD4 T
cells were stimulated in vivo. However, the absolute numbers of clonotype-positive CD25 CD4 T cells in the

Figure 7. CD25 CD4 T cells primarily proliferate to DCs as APCs. Proliferation was assessed by incorporation of [3H]thymidine for the last 12 h.
(A) 104 T cells were cultured for 3 d with BM-DCs, spleen CD8, or CD8 CD11c DCs matured by culture overnight in LPS, and CD19 B cells matured in LPS. The APCs were exposed to 1 mg/ml OVA before use. Data with APCs lacking OVA were 103 cpm and are omitted. (B) As in A, but
BM-DCs were compared with spleen CD8 or CD8 CD11c DCs, either fresh immature cells or matured by culture overnight, along with 1 g/ml
DO11.10 peptide. (C) As in A, but DCs were compared with macrophages, either PECs, TGC-elicited PEC, or IFN-–treated TGC-PEC. (D) CD25
CD4 T cells from DO11.10 mice were cultured for 3 d with lymph node CD11c DCs from untreated mice, or mice 5 d after CFA injection s.c. Representative results from three similar experiments.
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flammatory cytokine GM-CSF and in the presence of
other phagocytes like neutrophils and macrophages, we
turned our attention to DCs from lymph nodes expanded
in the presence of an in vivo inflammatory stimulus, CFA.
The CD11c DCs from CFA-stimulated lymph nodes
were fourfold more numerous. On a per cell basis, CFAelicited lymph node DCs were stronger stimulators of the
growth of CD25 CD4 regulatory T cells, compared with
lymph node DCs in the steady state (Fig. 7 D). Therefore,
DCs seem to be the major APC capable of stimulating
CD25 CD4 T cell growth, but DCs acquire greater activity under inflammatory conditions, either GM-CSF in
vitro or CFA in vivo.
CD25 CD4 Regulatory T Cells Can Be Expanded In
Vivo by Antigen-bearing Mature DCs. To extend the findings to the growth of CD25 CD4 T cells in vivo, we purified CD25 and CD25 CD4 T cells from OVA-specific
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Discussion
Our observations provide some new perspectives on the
function of CD25 CD4 T cells and DCs. These T cells
are known to suppress other T cells mediating autoimmunity, graft rejection, graft versus host disease, and resistance
to tumors (for review see 1, 2, and 34), but CD25 CD4
T cells have always exhibited anergy in experimental studies, being unable to expand in response to mitogens (14,
15) and specific antigens (14, 16, 18, 35–37) and unable to
produce IL-2 (14, 15). Previous work has used spleen cells
as APCs. Spleen cells are a mixture of many cell types, with
only 1–1.5% being DCs, and the majority are in an immature state (30). In contrast, when DCs are added in relatively high numbers, CD25 CD4 T cells proliferate extensively in an antigen-dependent fashion, even in the
absence of exogenous IL-2 (Figs. 1 and 2), which has had
to be used at high doses in all previous work to expand
these T cells in culture (14, 15). The expanded T cells, after
several cycles of cell division, retain their suppressor cell
phenotype and function (Fig. 6). The DCs are most active
when generated under inflammatory conditions, e.g., when
the DCs are derived from BM progenitors with GM-CSF
in vitro or after challenge with an inflammatory adjuvant
(CFA) in vivo, but other APCs like macrophages and B
cells seem unable to expand CD25 CD4 T cells (Fig. 7).

Figure
8. DCs stimulate
CD25 CD4 and CD25
CD4 T cell proliferation in
vivo. (A) 0.7  10 6 CFSElabeled T cells were injected i.v.
and stimulated with 2  105
marrow DCs or DC-OVA injected s.c. into the footpads 1 d
later. Clonotype positive (KJ1.26)
TCR transgenic T cells (top, circle) were analyzed for proliferation and expression of CD25 3 d
later by dilution of the CFSE label in draining or distal (mesenteric) lymph nodes. (B) As in A,
but OVA antigen was delivered
by the injection of 25 g soluble
OVA into each footpad in the
steady state. One representative
result of three similar experiments.
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lymphoid organs were always lower than expanded CD25
CD4 T cells (unpublished data). Interestingly, the levels of
CD25 on the expanding CD25 CD4 regulatory T cells
were increased during their growth in vivo and were much
higher at day 3 than the CD25 expressed by responding
CD25 CD4 T cells (Fig. 8). These results in mice replicate the findings in vitro that DCs are able to expand
CD25 CD4 regulatory T cells.
To determine if DCs in vivo in the steady state could
stimulate the expansion of CD25 CD4 T cells, the latter
were adoptively transferred into mice followed by challenge with soluble OVA in the absence of any adjuvant or
inflammatory stimulus. It is known that DCs are the main
cell type that successfully captures and presents OVA for
stimulation of T cells (30). Again, the adoptively transferred
CD25 CD4 and CD25 CD4 T cells each underwent
several cycles of cell division in vivo in the draining lymph
nodes in response to OVA (Fig. 8 B). As in the case of proliferation stimulated by injected mature DCs, CD25
CD4 T cells stimulated in the steady state continued to
express high levels of CD25, whereas their CD25 CD4
counterparts had not yet up-regulated CD25 expression at
this time point (Fig. 8 B). Therefore, CD25 CD4 T cells,
and not contaminants in the adoptively transferred populations, proliferate to antigen-bearing DCs in the steady state
and after immigration from peripheral tissues.
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35–37, 43), but a self-peptide acting on an endogenous
TCR might be required to positively select the CD25
CD4 fraction of DO11.10 T cells. Walker et al. (44) in
this issue report the proliferation of CD25 CD4 T cells
from DO11.10 mice in response to immunization with antigen in Freund’s adjuvant in vivo. Interestingly, they find
that CD25 CD4 T cells from DO11.10 mice also respond to OVA antigen expressed as a surrogate self-antigen
in tissue cells, consistent with our data that immature
steady-state DCs can capture antigens for stimulation of
CD25 CD4 T cells.
Importantly, maturing DCs are not subject to suppression by CD25 CD4 T cells (Fig. 1 A). It has recently
been reported that DCs stimulated via microbial ligands
can produce IL-6 and block the suppressive activity of
CD25 CD4 T cells (26). Our current data relate to the
expansion of CD25 CD4 T cells that can suppress responses in standard assay systems involving splenic APCs
rather than maturing DCs. The target for the action of the
suppressor T cells is not yet apparent and may include a less
stimulatory form of DC than the cells found in lymph
nodes in the steady state or BM cultures expanded with
GM-CSF. Nevertheless, in this issue, Oldenhove et al. (45)
have now considered the suppression of mature DC function in vivo. After eliminating CD25 CD4 T cells, they
find that mature DCs stimulate larger Th1 T cell and CTL
responses in vivo.
Our studies deal with mouse CD25 CD4 regulatory T
cells, but other reports have shown that their human counterparts respond poorly to mature monocyte-derived DCs
in the allogeneic mixed leukocyte reaction (46–48). The
work with human cells has used lower DC/T cell ratios
(1:10) relative to our studies, as well as allogeneic responder
T cells rather than highly enriched antigen-specific TCR
transgenic T cells. In addition, the CD25 CD4 human
T cell populations have the capacity to produce IL-10,
whereas we do not detect this immunosuppressive cytokine
in our cocultures of DCs and CD25 CD4 T cells.
The observation that mature DCs actively expand suppressive CD25 CD4 T cells provides a new mechanism
for DCs to avoid the induction of autoimmunity (27, 49).
Before infection, the thymus has already produced CD25
CD4 T cells capable of regulating autoimmunity (for review see 1, 2, and 34). We would like to suggest that these
T cells are able to expand in the periphery under several
circumstances. When DCs in lymph nodes are processing
and presenting self-antigens in the steady state (50–52), the
data in Fig. 8 B indicate that CD25 CD4 T cells would
undergo expansion. Likewise, when mature DCs are inducing immune responses in the lymph node, with concomitant IL-2 production, bystander CD25 CD4 T cells
would be expected to expand, as indicated by the data in
Figs. 3, A and B, and 4 B. Additionally, when maturing
DCs are themselves presenting cognate self-antigens, thymic-derived CD25 CD4 T cells would be expected to
expand vigorously (Figs. 1–4 and 8 A), and serve to suppress autoreactive responses by other APCs. These potential roles for DCs in controlling CD25 CD4 T cells have
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One mechanism for DC function involves cell surface
molecule(s) on DCs because aldehyde-fixed DCs are active
in expanding CD25 CD4 T cells and cell contact is essential (Figs. 4 and 5). We find that CD80 and/or CD86
contribute substantially as costimulatory molecules, though
DCs that are deficient in both CD80 and CD86 still retain
some stimulatory function (Fig. 4 C) implying the existence of additional costimulators on these cells. The need
for CD80 and CD86 is consistent with the in vivo observation that blockade of these molecules in diabetes-prone
nonobese diabetic mice reduces regulatory T cells and enhances autoimmune disease (38).
Another mechanism of DC function involves the production of soluble factors such as IL-2 (Fig. 3). We first
found that DCs from IL-2/ mice could stimulate the expansion of CD25 CD4 T cells in the absence of exogenous IL-2. This expansion could be blocked by 50% with
anti-CD25 antibody and was accompanied by small
amounts of IL-2 release into the medium, presumably from
the T cells. These results are consistent with the in vivo
findings that IL-2 and CD25 are important for the maintenance of peripheral CD25 CD4 T cells (39, 40). Again,
IL-2 blockade did not fully suppress the response of
CD25 CD4 T cells to DCs, so that additional growth
factors are likely to be important after an initial cell contact–dependent activation by DCs (Fig. 5).
Although CD25 CD4 T cells are classically anergic to
TCR stimulation, they are known to proliferate under select circumstances. For example, it has just been reported
that LPS directly induces the proliferation of CD25 CD4
T cells through Toll-like receptor 4 (41), but high doses of
LPS (10 g/ml) are needed. In lymphopenic hosts, CD25
CD4 T cells can undergo division (17), and this depends
upon MHC class II expressed by host cells (18), perhaps
expressed by DCs capturing self-antigens in the steady state
given our observations (Fig. 8 B). A 20-fold expansion of
CD25 CD4 T cells takes place over 7–9 wk after transfer
into newborn IL-2R–deficient mice (42). Our results involve the transfer of CD25 CD4 T cells into intact adult
mice, followed by a rapid proliferative response to stimulation by antigen processed by DCs (Fig. 8). These antigendependent responses are not due to contaminating CD25
CD4 T cells, which expressed much lower levels of CD25
when studied in parallel (Fig. 8).
We have used T cells from a TCR transgenic line that is
specific for a foreign antigen, OVA. However, CD25
CD4 T cells with a high affinity for self-antigens can be
selected during development in the thymus (36). In TCR
transgenic mice, particularly the DO11.10 mice that we
studied, CD25 CD4 T cells express an endogenous
TCR chain in addition to that expressed by the transgenic
TCR (35, 43). We presume that this endogenous TCR allows for the selection of the CD25 CD4 T cells in the
thymus because these cells are not found when the transgene is bred into a RAG knockout background (43). The
OVA-specific TCR allows the CD25 CD4 T cells from
these mice to suppress other T cells after stimulation with
OVA-specific peptide as previously described (14, 16, 18,

been identified here through the study of OVA-specific
TCR transgenic T cells. The relevance of the findings to
the control of bone fide autoimmunity and other immune
responses will now need to be pursued directly.
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